Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924087 | 0.88 | MCHR1 (0.54) | MCHR1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL6812487 | 0.86 | MCHR1 (0.73) | MCHR1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL6925935 | 0.84 | MCHR1 (0.73) | MCHR1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL6928305 | 0.81 | MCHR1 (0.52) | MCHR1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL6924766 | 0.81 | MCHR1 (0.74) | MCHR1KDRMAPTLMNAALDH1A1 | |
| SCHEMBL6925419 | 0.81 | MCHR1 (0.74) | MCHR1KDRMAPTMEN1LMNA | |
| SCHEMBL6925940 | 0.80 | MAPT (0.77) | MCHR1KDRMAPTLMNAALDH1A1 | |
| SCHEMBL6807188 | 0.79 | MCHR1 (0.71) | MCHR1KDRMAPTMEN1KMT2A | |
| SCHEMBL6921877 | 0.79 | MCHR1 (0.71) | MCHR1KDRCHRM2MAPTLMNA | |
| SCHEMBL6921824 | 0.78 | MCHR1 (0.81) | MCHR1KDRCHRM2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | claimed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | claimed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | claimed |
| JP-2002511879-A | — | — | 2002-04-16 | — | — | JP | claimed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | claimed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| US-6515027-B1 | Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 | SMITHKLINE BEECHAM CORP. | 2003-02-04 | — | — | US | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
| EP-1001766-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1001766-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999001127-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | MCHR1 133/4885HDAC3 304/4885HDAC11 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.